- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04837092
Phase I/II Study of FR104 First Administration In Patient With Renal Transplantation: FIRsT Study (FIRsT)
November 14, 2023 updated by: Nantes University Hospital
A Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of FR104, a Novel Antagonist Pegylated Anti-CD28 Fab' Antibody Fragment in de Novo Renal Transplant Patients
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) of FR104 as well as its potential clinical effect on acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gilles BLANCHO
- Phone Number: 0240087439
- Email: gilles.blancho@chu-nantes.fr
Study Locations
-
-
-
Nantes, France
- Blancho
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female ≥ 18 years old
- Signed and dated written informed consent prior to any study procedure
- First kidney transplantation
- Willing and able to participate to the study
- Women of childbearing potential must use appropriate method(s) of contraception during the clinical trial (oral contraception, implant or intrauterine device) throughout the study period and for 90 days after the last dose of FR104
- Women of childbearing potential must have a negative urinary pregnancy test the day of transplantation
- All sexually active male subjects must agree to use an adequate method of contraception throughout the study period and for 90 days after the last dose of study drug and agree to no sperm donation until the end of the study, or for 90 days after the last dose of FR104, whichever is longer
- Recipient of a kidney from deceased donor -
- Recipient of a de novo kidney transplant able to start the immunosuppressive regimen at the protocol-specified time point
- Recipients of a kidney with a cold ischemia time < 36 hours
- Patients with French social security
Exclusion Criteria:
- Recipient of a kidney from living donor
Patient at high immunological risk of rejection as determined for assessment of anti-donor reactivity:
High TGI >20% or Presence of pre-formed DSA with MFI>500 (results 12 weeks prior to enrollment are acceptable if no blood transfusion or abortion occurred during this period)
- Any retransplantation and combined transplantations
- ABO incompatible transplantation
- HIV-positive, EBV-negative or suffering active viral hepatitis B (AgHbs positive excluded) or hepatitis C, syphilis serology- positive recipient
- CMV negative recipients of CMV positive donors (R-D+)
- Patient with known history of tuberculosis
- Uncontrolled concomitant infection or any other unstable medical condition (heart failure, severe liver disease, psychiatric disorders, substance abuse) that could interfere with the study objectives
- A known allergy, hypersensitivity, or intolerance to the study drug, or to any of its components
- Previous history of cancer (except appropriately treated non-melanoma skin cancer or localized cervical cancer, or other local tumors considered cured)
- Pregnant woman or likely to become pregnant or nursing
- Patient under guardianship or trusteeship
- Patient participating in another interventional clinical trial
- Live viral or bacterial vaccines/treatment agents given from 3 months prior to FR104 administration (12 months for BCG vaccine)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FR104 Treatment
|
FR104 treatment administration at day 0, day 14 then every 28 days until month 12
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of FR104 - Adverse Events with a focus on infectious complications. In particular
Time Frame: Until Month 12
|
Type, severity (grades 3 and 4 adverse effects)., number and percent of Adverse Events with a focus on infectious complications.
In particular, the following cumulative incidences will be calculated: Incidence of bacterial, fungal, viral, or parasitic infection, incidence of new malignancies, lymphopenia, anemia, leucopenia, cytopenia or biochemical disturbances related to the study drug.
|
Until Month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy on Renal function
Time Frame: Month 6 and Month 12
|
Calculated glomerular filtration rate (CKD EPI) at each visit.
|
Month 6 and Month 12
|
Efficacy on Biopsy-proven acute rejection (BPAR)
Time Frame: Month 12
|
Acute cellular rejection seen on renal biopsy for cause up to Month 12 (per Banff criteria 2017)
|
Month 12
|
Efficacy on clinically-treated acute rejections
Time Frame: Month 12
|
Graft acute rejection up to Month 12. Number of AE related to treatment.
Incidence and grade of rejection proven on Biopsy analysed after M12.
|
Month 12
|
Efficacy on steroid-resistant episodes
Time Frame: Month 12
|
Steroid resistant episodes up to Month 12. Corticoresistant rejection up to month 12 defined as non response at day 5-6 after steroid boluses.
|
Month 12
|
Efficacy on multiples rejection episodes
Time Frame: Month 12
|
Rejection episodes up to Month 12. Number of rejection after M12.
According to histology.
Incidence of biopsy-proven rejection (by banff grade).
|
Month 12
|
Efficacy on chronic allograft nephropathy
Time Frame: Month 12
|
Chronic allograft nephropathy seen on renal biopsy for cause up to Month 12
|
Month 12
|
Efficacy on graft survival
Time Frame: Month 12
|
Renal dialysis or new kidney transplant up to Month 12
|
Month 12
|
Treatment failure time
Time Frame: Month 12
|
Time to treatment failure up to M12 (Biopsy-proven acute rejection, Graft Loss or Death)
|
Month 12
|
Evaluate the first Biopsy-proven acute rejection time
Time Frame: Month 12
|
Time to the first Biopsy-proven acute rejection
|
Month 12
|
Evaluate the appearance of Donor specific Antibodies
Time Frame: Month 12
|
Appearance of Donor specific Antibodies
|
Month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2021
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
December 3, 2020
First Submitted That Met QC Criteria
April 6, 2021
First Posted (Actual)
April 8, 2021
Study Record Updates
Last Update Posted (Actual)
November 15, 2023
Last Update Submitted That Met QC Criteria
November 14, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RC20_0007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on FR104
-
OSE ImmunotherapeuticsCompletedRheumatoid Arthritis | Complication of TransplantBelgium